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Abstract
Repair of sustained liver injury results in fibrosis (i.e. the
accumulation of extracellular matrix proteins), and ultimately
the complete distortion of parenchymal architecture of the
liver, which we call cirrhosis. Detecting and staging of fibrosis is
thus a mainstay in the management of chronic liver diseases,
since many clinically relevant decisions, such as starting
treatment and/or monitoring for complications including hep-
atocellular carcinoma, may depend on it. The gold standard for
fibrosis staging is liver biopsy, the role of which, however, is
questioned nowadays because of cost, hazards and poor
acceptance by patients. On the other hand, imaging techni-
ques and/or measurement of direct and indirect serum
markers have not proved to be completely satisfactory under
all circumstances as alternatives to liver biopsy. Making pro-
gress in this field is nowmore crucial than ever, since treatments
for established fibrosis appear on the horizon. Fine dissection of
the pathways involved in the pathophysiology of liver diseases
has put forward several novel candidate biomarkers of liver
fibrosis, such as growth arrest-specific6, Mac-2-binding protein,
osteopontin, placental growth factor, growth/differentiation fac-
tor 15 and hepatocyte growth factor. All molecules have been
suggested to have potential to complement or substitute
methods currently used to stage liver diseases. Here, we review
the pros and cons for their use in this setting.
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Introduction
Hepatic fibrosis is the overly exuberant accumulation of
extracellular matrix proteins, including collagen, typically
triggered by chronic injury of the liver parenchyma with an
inflammatory component. This process, analogous to wound
healing, may disrupt the hepatic architecture and results in
hepatocellular dysfunction and portal hypertension, two of
the main features of cirrhosis.1,2 Indeed, to the multiplicity of
factors (viral, toxic, genetic, nutritional, etc.) causing liver
diseases, the counterpart is a relative monotony of pathological
features, including degeneration and necrosis of hepatocytes,
replacement of liver parenchyma by fibrotic tissue and regen-
erative nodules and loss of liver function. These events are in
fact the result of the activation of common pro-inflammatory
and pro-fibrotic pathways.3–5
Accurately defining the fibrosis stage reached by a patient
along the course of his/her disease is of quintessential clinical
importance, since crucial decisions, such as starting monitor-
ing for complications (i.e. esophageal varices or hepatocel-
lular carcinoma (HCC)), depend on it. Unfortunately, the
medical history and physical examination do not always
provide reliable clues for the detection of advanced fibrosis,
since the classical signs of liver diseases are commonly
absent or subtle in early cirrhosis.6,7 The gold standard for
fibrosis detection and quantification is liver biopsy, a proce-
dure poorly accepted by patients, who perceive it as unduly
aggressive and risky.8 In the past decade, several methods to
stage chronic liver disease noninvasively have been proposed
or are under evaluation/validation. They fall into the following
two broad categories: a) imaging techniques, and b) serum
markers, sometimes combined into artificial intelligence
algorithms.9
Though the noninvasive alternatives have largely replaced
liver biopsy for many indications, they also have pitfalls.
Ultrasonography, for example, can suggest the presence of
fibrosis and cirrhosis but it is neither sensitive nor specific in
doing it, performing significantly better only in late stages
of liver cirrhosis, when the signs of portal hypertension
develop.10 Computed tomography and magnetic resonance
are more sensitive and specific, but they are also burdened
by high costs and inadequate inter-rater reliability among dif-
ferent radiologists; moreover, the extensive use of computed
tomography scan is limited by radiological risks.11 Finally,
transient elastography, besides requiring expensive equip-
ment, maybe inaccurate in obese patients and may lead to
over-estimation of fibrosis in patients with high necroinflam-
matory activity.12 Being the result of the sum of inflammation
and fibrosis in the liver parenchyma, liver stiffness per semay
not be the ideal candidate to monitor for fibrosis regression.
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The ability of the liver to either produce or modify
hundreds of chemicals has long been exploited to estimate,
from the changes in their blood concentration, the degree to
which liver function is impaired and/or organ damage is
extensive. Indeed, liver biochemistry panels are included in
almost all laboratory routines, being informative, relatively
cheap and prone to repeat testing. Conceptually, fibrosis
makes no exception. By-products spilling in the blood as a
result of the deposition of excess extracellular matrix can be
taken as a proxy measure of what is occurring in the liver
parenchyma.
Alternatively, patients can be profiled based on artificial
intelligence algorithms that produce scores by combining
different parameters, including demographics and blood cell
counts, such as the aspartate aminotransferase-to-platelet
ratio (APRI),13 fibrosis-414 or Fibro index.15 Unfortunately,
neither the former nor the latter approach have produced
highly accurate results for liver fibrosis assessment to
date,16 and their use in clinical practice is not comparable to
that of prognostic scores, such as the Child-Pugh-Turcotte
classification system17 and the Model for End-stage Liver
Disease score.18 In this context, we also need to account for
some derived scores, such as FibroMeter19 and FibroTest,20
which include more specific blood tests that are not routinely
available. Again, the lines of evidence about their reliability
and cost-effectiveness are not enough to support their use in
clinical practice.
There is always room for improvement. Recently, for
example, the use of nt-pro-brain natriuretic peptide and copep-
tin, prognostic biomarkers in patients with heart failure,21,22
has been extended to liver cirrhosis;23,24 their concentrations
in blood bear a strict relationship to the hemodynamic changes
that parallel the progression of liver disease. With putative
treatments for liver fibrosis appearing on the horizon, the
race to discover the holy grail of a liquid biopsy able to
monitor its progression and regression is on. In the present
paper we will review current lines of evidence supporting the
use of some of the less known but still promising novel bio-
markers for the detection of fibrosis in patients with chronic
liver diseases.
Growth arrest-specific 6 (Gas6)
Gas6 is the circulating ligand of three different tyrosine kinase
receptors, collectively named TAM, an acronym for Tyro3,
Axl and MerTK. The human gene was cloned in 1993 and
encodes for a vitamin K-dependent protein which is expressed
in different tissues, such as the gut, bone marrow, endothelial
cells and fibroblasts.25–27 The Gas6/TAM system is highly
pleiotropic and has many biological functions. Gas6 and TAM
regulate cell growth and they have been claimed as potential
actors in oncogenesis.28 Moreover, Gas6 and TAM are implied
in the activity of the immune system. MerTK and Axl have
been isolated from circulating monocytes and tissue macro-
phages,29,30 and their activation by Gas6 down-regulates the
expression of pro-inflammatory cytokines.31 Furthermore, this
system is directly involved in the clearance of apoptotic bodies.
In fact, Gas6 recognizes phosphatidylserine, a lipid normally
expressed on the inner face of the plasma membrane and
exposed on the external membrane during apoptosis; by doing
it, Gas6 bridges this lipid with TAM receptors, driving macro-
phages to the recognition of apoptotic cells and to their subse-
quent phagocytosis.32
It is, therefore, not surprising that a dysfunction of this
system has been linked to the development of autoimmune
and degenerative diseases, since an impaired clearance of
apoptotic bodies and an inappropriate inflammatory response
are considered critical for the deranged immune response
observed in these conditions. On these premises, Gas6 and
TAM have been found to be related to rheumatoid arthritis,33
connective tissue diseases,34,35 Alzheimer’s disease36 and
multiple sclerosis.37 Furthermore, TAM are involved in hemo-
stasis, also being receptors of protein S, a master regulator of
the coagulative cascade; Gas6 seems to play a complemen-
tary role in platelet function38 and it has been proposed as a
biomarker for the diagnosis of pulmonary embolism.39
More recently, the Gas6/TAM interaction has been
described to be relevant in inflammatory and repair processes
of the liver; in fact, Gas6 seems to play a protective role in
response to liver injury. After an acute or chronic injury, repair
involves macrophages and hepatic stellate cells (HSCs)
activated into myofibroblastic cells (HSCs/MFBs), which
produce cytokines and matrix proteins. It has been shown
in animal models that Gas6 expression by macrophages,
HSCs and HSCs/MFBs is significantly up-regulated in injured
areas. In this context, Gas6 exerts an anti-apoptotic effect on
both HSCs and HSCs/MFBs, acting as a survival factor for
these cells, probably supporting transient HSC/MFB accumu-
lation during liver healing.40
Consistent with this finding, in Gas6−/− knock-out (KO)
mice, a defective wound healing after carbon tetrachloride-
induced liver damage has been reported, with reduced
Kupffer cell activation and decreased macrophage and HSC/
MFB recruitment in damaged areas.41 Similarly, Gas6−/− KO
mice are more prone to severe liver damage after ischemia/
reperfusion injury and the administration of recombinant
Gas6 has a protective role either in wild-type or in KO
mice.42 This protective role is played at the expense of a fibro-
genic effect, however. In fact, Gas6-deficient mice also
exhibited reduced liver fibrosis as a consequence of defective
macrophage recruitment, inflammatory response and HSC/
MFB activation compared with wild-type animals.43
Bárcena et al.44 recently demonstrated that blockade of
the Gas6/Axl pathway down-regulates HSC activation, colla-
gen deposition and liver fibrogenesis, even postulating a
potential therapeutic role for Axl inhibition in the prevention
of liver fibrosis. In the same paper, the authors firstly
observed a correlation between Gas6 plasma concentration
and the progression of liver disease in a group of patients
affected by alcoholic liver disease and in a group of hepatitis
C virus (HCV)-infected subjects. According to these authors,
Gas6 concentrations were significantly higher in patients
than in healthy controls and progressively increased from
F0/F1 to compensated and finally to decompensated cirrho-
sis.44 However, the activity of Gas6 in this context probably
also implies the activation of MerTK, as suggested by the
observation that a specific polymorphism of its gene, asso-
ciated with lower intrahepatic expression of MerTK, is pro-
tective against F2-F4 fibrosis in patients with nonalcoholic
fatty liver disease (NAFLD).45
On these premises our group recently published a paper
demonstrating that Gas6 plasma concentration directly cor-
relates with liver stiffness assessed by liver elastography and
is higher in patients with higher degrees of fibrosis assessed
by liver biopsy. The diagnostic accuracy was comparable
to that of liver elastography.46 Of note, Gas6 is also able to
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predict one of the most relevant complications of liver cirrho-
sis, esophageal varices.47
Mac-2 binding protein (M2BP)
Amongst the most promising molecules identified by proteo-
mics as a candidate marker of fibrosis is M2BP.48 M2BP is a
90-kDa glycoprotein, able to promote cell adhesion and to
bind selectively to several collagen types and fibronectin, as
well as to galectin-3 (formerly known as Mac-2). This protein
is secreted by different cell types and, interestingly, it oligo-
merizes in large ring structures. It has been shown that the
biological behavior of M2BP is modified by liver disease pro-
gression as a consequence of changes in N-glycosylation; on
this basis, a specific test has been developed by Japanese
investigators using a Wisteria floribunda agglutinin lectin
probe which is able to discriminate this altered N-glycans
profile of M2BP. Therefore, Wisteria floribunda agglutinin-
positive Mac-2 binding protein (WFA+-M2BP) has been pro-
posed as a unique glycobiomarker associated with progression
of liver disease.49
Since its development, this test has been evaluated in
many cohorts of patients with chronic liver diseases of differ-
ent etiologies. Serum level of WFA+-M2BP has been validated
as a marker of liver fibrosis in HCV50,51 and hepatitis B virus
(HBV)52 infected subjects, in NAFLD,53 in primary biliary cir-
rhosis,54 and in autoimmune hepatitis.55 Moreover, serum
levels of WFA+-M2BP are predictive of the development of
HCC in patients affected by chronic HCV-related liver disease.
In fact, in HCV infected subjects, the 10-year cumulative risk of
HCC rises from 1.1% to 54.1% for different, increasing thresh-
olds of WFA+-M2BP plasma concentrations.56 Similarly, WFA+-
M2BP plasma concentration was an independent risk factor for
HCC in a retrospective cohort of 1323 patients affected by
chronic HBV-related liver disease. Along a median follow-up
period of 60.3 months, 52 (3.9%) patients developed HCC.
In multivariate analysis, WFA+-M2BP predicted HCC develop-
ment with an adjusted hazard ratio of 1.143 (95% confidence
interval: 1.139–1.829), together with male sex and diabetes.
Interestingly, the predictive value of WFA+-M2BP is even
higher in patients without cirrhosis. These findings suggest
a potential role for WFA+-M2BP in the surveillance strategies
for HCC development in the clinical course of chronic liver
diseases.57
Although growing evidence links M2BP to liver fibrosis, it
is still not clear whether the increase of its plasma concen-
tration is a simple epiphenomenon or if this molecule plays
a pathogenetic role. Recently, an increasing proportion of
WFA+-M2BP-positive cells has been shown in liver sections
for increasing degrees of fibrosis. According to recent lines of
evidence, HSCs are the main cell type responsible for WFA+-
M2BP secretion, and probably the interaction of M2BP with
Mac-2 expressing Kupffer cells possibly contributing to
a-smooth muscle actin expression.58
However, M2BP is not a disease-specific marker. First of all,
it seems to mark fibrotic processes in general. Increased
WFA+-M2BP plasma concentrations have been described in
idiopathic pulmonary fibrosis and in chronic pancreatitis.59,60
Finally, M2BP probably has a role in cell transformation and
cancer spreading. Therefore, many authors have investigated
M2BP concentrations in different neoplastic conditions. A role
for this biomarker has been postulated and proved for
lung,61,62 prostate,63,64 pancreatic,65 gastric66 and colorectal
cancer.67
Osteopontin (OPN)
OPN is a 32-kDa secreted, extracellular matrix glycosylated
phosphoprotein, encoded by a gene located on chromosome
4 (4q13). OPN is characterized by a wide conformational
flexibility due to extensive posttranslational modification and
leading to heterogeneity in phosphorylation, glycosylation
and sulphation;68 this feature confers OPN different func-
tions, depending on the microenvironment in which it acts.
As a pleotropic cytokine, OPN is involved in different physio-
logical and pathological processes, including inflammation,69
cancer progression69,70 and wound healing.71 Many data in
the literature confirm OPN as a major determinant of liver
fibrosis, both in animal models and in humans, regardless to
the cause of liver damage.72
In 2012, Urtasun et al.73 demonstrated that mice over-
expressing the OPN gene develop liver fibrosis spontane-
ously; these Authors found that the effect is mediated by
PI3K/pAkt/NF-kB activation which follows the interaction
between OPN and avß3 integrin on the HSC surface, with con-
sequent collagen-I up-regulation and fibrosis formation.73
OPN also plays an important role in fibrillar collagen deposi-
tion at periportal spaces, mediated through the activation of
oval cells (OCs).OPN prompts OCs to differentiate into biliary
epithelial cells (BECs) and causes an inflammatory response,
called ductular reaction, which involves BECs and inflamma-
tory cells in the portal tract interface. The ductular reaction is
characterized by the production of different molecules that
sustain portal fibrosis via the activation of extracellular
matrix, HSCs and portal fibroblasts.
Wang et al.74 studied the role of OPN in fibrogenesis using
two murine models of chronic liver injury, based on chronic
thioacetamide administration and common bile duct ligation
both in wild-type and OPN null mice. The results pointed out
that OPN is a major determinant of the dysregulated response
to liver injury that leads to liver fibrosis. The Authors discov-
ered that OPN−/−mice develop less OC and BEC proliferation,
less ductular reaction and less collagen-I deposition with
respect to wild-type mice. In vitro experiments confirmed
the ability of OPN for increasing OC and BEC proliferation. In
summary, these findings indicate that OPN, via its interaction
with extracellular matrix and adhesionmolecules, is an impor-
tant activator of different cell populations and of the matrix
leading to OC proliferation, ductular reaction and fibrogene-
sis. In this scenario, activated HSCs seem to exert a pos-
itive feedback on ductular reaction, inducing a vicious circle
in which OPN is involved with a pivotal role. The Authors’
hypothesis is that OPN may be one of the major mediators
inducing an inflammatory milieu that guides OC proliferation
and differentiation, collagen-I up-regulation and TGF-ß
over-expression.74 A recent study confirmed this hypothesis
and identified the high-mobility group box-1, a chromosomal
protein involved in DNA replication, as the mediator of the
OPN induced collagen-I up-regulation.75
These preclinical studies support the use of OPN as a
biomarker of fibrosis, of portal hypertension and of adverse
outcome in patients affected by chronic liver disease. Several
clinical studies confirmed this hypothesis and suggested the
use of OPN as a biomarker of liver fibrosis in HBV chronic
infection,76 HCV chronic infection77 and in alcohol-induced
liver disease.78 A strong correlation between OPN plasma
concentration and the degree of fibrosis, evaluated by liver
biopsy, was found by Matsue et al.79 in a population of 115
HCV infected patients; they divided their patients into five
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groups according to the histological degree of fibrosis (F0, F1,
F2, F3 and F4) and evaluated serum concentrations of differ-
ent biomarkers (platelet count, and OPN, hyaluronic acid and
collagen IV concentrations) and computed scores as APRI and
Fibro-Test. In this study, OPN presented as the best diagnostic
marker for fibrosis; its plasma concentration, in fact, was sig-
nificantly different in all the comparisons between groups and
the receiver operating characteristic curves allowed for iden-
tification of OPN cut-offs able to distinguish F1 versus F2/F3/
F4 patients (OPN: 83 ng/mL; area under the curve (AUC):
0.997), F1/F2 versus F3/F4 patients (OPN: 124 ng/mL; AUC:
0.999) and F1/F2/F3 versus F4 patients (OPN: 152 ng/mL;
AUC: 0.945). None of the other parameters considered gave
similar results and the Authors concluded that OPN is an inde-
pendent predictor of the extent of liver fibrosis in HCV patients
and could be used as a non-invasive biomarker to assess the
grade of fibrosis in HCV patients. Its use could help to reduce
the number of liver biopsies.79
Other studies evaluated the relationship between OPN and
the presence of complications of cirrhosis, as portal hyper-
tension. In 2016, for example, a study involving 154 cirrhotic
patients, mainly affected by alcoholic cirrhosis, demonstrated
a relationship between OPN plasma concentration and the
hepatic venous pressure gradient (HVPG) measured with the
classic wedge technique. The Authors found that OPN plasma
concentration was significantly increased in cirrhotic patients
with respect to controls (107 vs. 55 ng/mL respectively).
Within cirrhotics, OPN plasma concentration showed a stat-
istically significant correlation with HVPG upon linear regres-
sion analysis. A cut-off value of OPN set at 80 ng/mL showed a
sensitivity of 75% and a specificity of 63% in identifying
patients with a HVPG of >10 mmHg (AUC: 0.763). Setting the
OPN cut-off at 90 ng/mL, the data allowed for identification of
patients at high risk for variceal bleeding (i.e. patients with
HVPG >12 mmHg) with a sensitivity of 71% and a specificity
of 62% (AUC: 0.72). These Authors also evaluated the
prognostic value of OPN, with a mean follow-up time of 3.7
± 2.6 years. Kaplan-Meier curves analysis showed a signifi-
cantly superior cumulative probability of survival in patients
with OPN <80 ng/dL with respect to patients with OPN above
this cut-off value (56% vs. 37% respectively with an odds
ratio of 2.23). The same trend was confirmed upon stratify-
ing of patients using HVPG (above or below 10 mmHg; odds
ratio: 2.92).
Overall, these data demonstrate the direct involvement of
OPN in the scarring process affecting the liver and the strong
correlation between the OPN plasma concentration and the
liver fibrosis progression. Other recent studies have pointed
out the role of OPN in the development and progression
of HCC.80
In conclusion, OPN seems to be a reliable biomarker for
the noninvasive staging of liver fibrosis in different chronic
liver diseases; moreover, since many lines of evidence
support its important role in the pathophysiology of fib-
rosis, it is tempting to speculate in favor of a possible role
for the OPN/collagen-I axis as a target for future anti-
fibrotic therapies.
Placental growth factor (PlGF)
PlGF is a member of the vascular endothelial growth factor
family, discovered and cloned in the early ‘90s.81 PlGF acts as
a pro-angiogenic factor, enhancing the proliferation, migra-
tion and survival of endothelial cells. Moreover, it stimulates
proliferation of mesenchymal fibroblasts and regulates the
contractile response of mural cells, organized around the
endothelium. Finally, PlGF activates and attracts macro-
phages, which in turn release angiogenic and lymphangio-
genic factors and interferes with dendritic cell differentiation
and accumulation, as well as with antigen recognition. PlGF
and its pathway have been claimed as potentially relevant in
many different human diseases. One of the most promising
applications is chronic liver disease.82 The first paper linking
PlGF to liver fibrosis was published in 2005, when Salcedo-
Mora et al.83 reported an increased PlGF plasma concentra-
tion in patients with HCV-related chronic liver disease with
respect to healthy controls. More recently, the threshold of
20.2 pg/mL was reported to be 79% sensitive and 63% spe-
cific for liver fibrosis $F2.84
Interestingly, PlGF blockade does not affect the healthy
vasculature, thus limiting potential adverse reactions.85 Van
Steenkiste et al.,86 in 2011, reported a significant reduction in
angiogenesis, arteriogenesis, inflammation, fibrosis, and
portal hypertension in cirrhotic PlGF KO mice compared to
wild-type mice; similar results were obtained by pharmaco-
logically inhibiting PlGF.86 These findings have been recently
confirmed; PlGF expression by HSCs is up-regulated in the
carbon tetrachloride-induced rodent model of liver cirrhosis,
as well as in cirrhotic patients. The knock-down of PlGF attenu-
ates liver fibrosis. In fact, while 8 weeks after the carbon tetra-
chloride challenge of wild-type mice led to a remarkable
extent of fibrosis, PlGF KO mice exhibited thinner septa,
mild portal or pericellular fibrosis of the liver, and more pre-
served hepatic parenchyma. This was paralleled by a reduc-
tion in angiogenesis and in HSC proliferation and activation.87
On this basis, PlGF blockade has been postulated as a poten-
tially promising therapeutic target for the treatment of chronic
liver diseases.88
Growth differentiation factor 15 (GDF15)
GDF15 is a member of the TGF-b cytokine superfamily, cloned
in 1997 and also known by the name of macrophage
inhibitory cytokine 1.89 Its gene is located on chromosome
19p12–13.1 and codifies for a 40-kDa propeptide, cleaved
in the endoplasmic reticulum to release a 25-kDa active cir-
culating dimeric protein.90 Proinflammatory cytokines (i.e.
TNFa or interleukin-6) induce GDF15mRNA expression in acti-
vated macrophages, which suggests that GDF15 could act as
an autocrine inhibitor during the inflammatory response.
Probably, the suppression of proinflammatory cytokines
plays a role in the induction of immunotolerance towards
the fetus; in fact, GDF15 is expressed by the placenta in
large amounts under physiological conditions, with increasing
concentrations as pregnancy progresses.91 Moreover, low
serum levels of GDF15 between the 6th and 13th week of
gestation may predict miscarriage.92
Beside this postulated physiological activity, GDF15 induc-
tion has been observed in different pathological conditions, its
gene being over-expressed in response to diverse cellular
stress signals, such as hypoxia/anoxia, inflammation, acute
tissue injuries, and development of neoplasia. On these
bases, it has been studied as a biomarker for different
diseases. The greatest amount of evidence links GDF15 to
cardiovascular diseases and cancer. In fact, higher GDF15
plasma concentrations have been associated to a poor prog-
nosis in myocardial infarction, pulmonary thromboembolism
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and chronic heart failure but it has also been related to cancer
invasiveness, metastases and prognosis.93
In the last few years, several observations have hinted at a
potential role of this growth factor in chronic liver disease.
First of all, GDF15 expression in vitro in hepatoma cells is
dramatically enhanced by HCV infection, both at the mRNA
and the protein level. Moreover, higher GDF15 plasma con-
centrations are observed in patients affected by HCV and HBV
with respect to that in healthy controls.94 Considering what is
known about GDF15 physiology, this finding probably testifies
a response to the stress induced by viral infection and to the
consequent liver inflammation. As a further clue, an increase
in GDF15 expression has also been reported in mice sub-
jected to bile duct injury.95 A recent paper smartly elucidated
the role of GDF15 in liver pathology using animal models.
GDF15 is exclusively expressed by hepatocytes and not by
HSCs or by liver-resident macrophages. When hepatocytes
are stressed by different stimuli, i.e. alcohol or carbon tetra-
chloride, the expression of GDF15 gene is enhanced.
Despite being synthesized only by hepatocytes, GDF15
also has effects on HSCs and Kupffer cells. In fact, recombi-
nant GDF15 significantly decreases the lipopolysaccharide-
induced pro-inflammatory cytokines production by Kupffer
cells. Moreover, when Kupffer cells are co-cultured with GDF15
KO hepatocytes, the lipopolysaccharide-induced proinflam-
matory signature is significantly enhanced with respect to
co-culture with wild-type hepatocytes. This suggests an
important paracrine activity for GDF15. Finally, GDF15
deficiency in GDF15 KO mice enhances alcohol and carbon
tetrachloride-induced liver damage and fibrosis.96 Taken
together, these findings support the hypothesis that different
insults to liver parenchyma lead to the increase of GDF15
expression and, consequently, enhance its plasma levels;
as such, GDF15 would play a hepato-protective role. This
makes GDF15 potentially promising as a diagnostic bio-
marker of liver damage.
Nonetheless, although raised in cases of viral hepatitis,
GDF15 plasma concentration is a stronger marker of advanced
liver disease. In fact, in a study by Liu et al.,97 GDF15 was
significantly increased in HBV and HCV infected subjects with
respect to healthy controls, but the plasma concentrations
were 3 to 6 times higher in patients affected by liver cirrhosis
and HCC. Similarly, GDF15 is increased in cases of alcoholic
liver cirrhosis98 and in patients with advanced, biopsy-
proven, liver fibrosis in NAFLD.99
To the best of our knowledge, GDF15 has been tested as
diagnostic biomarker in two different studies. Lee et al.100
have demonstrated that GDF15 is able to predict chronic hep-
atitis, compensated liver cirrhosis and decompensated liver
cirrhosis, with an increasing degree of diagnostic accuracy.
More interestingly for the purpose of the present review, in
a European cohort of 834 patients, GDF15 was 94% sensitive
and 67% specific for the detection of a significant liver fibrosis
($F2, assessed by liver biopsy).84
Hepatocyte growth factor (HGF)
HGF is secreted by mesenchymal cells and cleaved by
extracellular proteases into a heterodimer composed by a
69-kDa a chain and 34-kDa b chain.101 Its receptor, tyrosine-
protein kinase Met (c-MET),is a class IV receptor tyrosine
kinase implicated in many physiological and pathological con-
ditions. c-MET is present on the surface of epithelial cells of
multiple organs including liver, pancreas, prostate, kidney,
lung and bronchus.102 Consequently, although originally iden-
tified and cloned as a potent mitogen for hepatocytes, HGF is
a strong protective and trophic factor for many tissues and
organs. For example, HGF plays a direct role in the prolifer-
ation and differentiation of erythroid progenitors.103 More-
over, HGF has a crucial role in wound healing and tissue
repair, being for example a protective, antifibrotic agent for
lung,104 kidney105,106 and heart107 as well.
On the other hand, over-activation of the HGF/c-MET
pathway has been shown in the pathogenesis and in the
prognosis of many different neoplastic conditions. c-MET is a
proto-oncogene, since an altered form, causing constitutive
kinase activity, has been cloned as a transforming factor from
a chemically-induced human osteosarcoma cell line.108 Fur-
thermore, a germline mutation of c-MET has been identified
as the cause of familial cases of hereditary papillary renal cell
carcinomas.109 Finally, c-MET over-expression is associated
with a poor prognosis in many human tumors, such as color-
ectal, ovarian and breast cancers.110
With regard to liver physiology and pathology, HGF is an
important hepato-protective and pro-regenerative factor
during liver injuries. The main intrahepatic source of HGF is
Kupffer cells; local pro-inflammatory cytokines expressed as
a consequence of liver damage are responsible for HGF gene
up-regulation.111 According to many pre-clinical data, HGF is
a promising therapeutic tool for liver diseases. In fact, differ-
ent experiments have been performed, including gene
therapy, transfection of mesenchymal cells over-expressing
HGF and the use of recombinant HGF. Independently from
the strategy adopted, HGF was able to suppress the develop-
ment of liver cirrhosis after toxic damage in experimental
rats112,113 and cholestatic damage,114 to prevent liver
failure115 and, in contrast to its anti-apoptotic activity on hep-
atocytes, to exert an inhibitory and pro-apoptotic effect on
HCC cells.116
As occurs for other hepato-protective molecules, the local
production of HGF is increased during chronic liver disease,
paralleling its increase in plasma concentration. Higher blood
concentrations of HGF have been found in cirrhotic patients
compared to controls and alcoholics without liver cirrhosis.
Moreover, significantly higher concentrations of HGF have
been observed in patients with Child class C liver cirrhosis
compared to patients with Child class A liver cirrhosis.117 Fur-
thermore, HGF plasma concentrations are able to effectively
distinguish liver cirrhosis from mild fibrosis in HCV infected
subjects.118 On these bases, HGF has been postulated as a
promising biomarker of liver fibrosis. According to a recent
study, HGF performs well as a biomarker of chronic liver
disease progression. In fact, it showed a 97% sensitivity
and a 64% specificity in the detection of a histological F2 or
higher stage of liver fibrosis.84
However, it should be noted that HGF is not hepato-specific
and its plasma concentration is increased in different patho-
logical conditions.119–121
Conclusions
The staging of liver fibrosis is of great importance in the
management of chronic liver diseases, but it is made difficult
by the inaccuracy of the methods currently available. This is
why the search for circulating biomarkers is clinically rele-
vant. Moreover, chronic liver diseases, though multifactorial,
share common pathways leading to fibrosis and cirrhosis,
which are still largely unknown. The discovery of novel
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biomarkers of liver fibrosis is, therefore, not only potentially
promising from a clinical point of view but could even
contribute to deepening our knowledge about the biological
mechanisms underlying the development of liver fibrosis.
Finally, the current treatment strategies are essentially
based on the removal of the cause, subsiding the fibrotic
process; a better knowledge of the mechanisms beyond the
development of liver cirrhosis could also give us the oppor-
tunity to develop new drugs directly targeting liver fibrosis.
In the last decades, dozens of putative molecules have
been proposed to monitor the clinical course of liver diseases.
In the present paper we have presented some of the most
promising, reviewing their biology and the line of evidence
supporting their use in clinical practice. These biomarkers
share some common pros and cons. First and foremost, they
can be tested easily, safely and inexpensively, overcoming
some of the main issues of the methods currently available (i.
e. liver biopsy and imaging techniques). These features make
them particularly suitable for repeat measurements and,
therefore, for monitoring patients during the clinical course
of their disease.
However, none of them is organ-specific. Their plasma
concentrations are generally increased not only as a conse-
quence of the development of liver fibrosis but also in several
other different conditions. Furthermore, hepatic and renal
clearance can interfere with circulating plasma levels. On
these premises, their routine use in clinical practice cannot be
currently supported. Other studies are required in the near
future to better validate these biomarkers, the use of which
cannot be established without a good selection of patients
undergoing tests of the dosages, to lower the number of false
positive subjects.
In the present paper we have reviewed the evidence about
the use of six different potential biomarkers of liver fibrosis. In
Table 1, we compared the diagnostic performance of these
molecules. We included those papers in which the diagnostic
performance has been analyzed with respect to the gold
standard - the liver biopsy. It is evident that the comparison
Table 1. Diagnostic value of candidate biomarkers of liver fibrosis
Value Sens Spec
Predictive
value AUC
Publication,
yearRef Etiology
Definition of
fibrosis
Gas6 30 ng/mL 84% 56% N/A 0.734 Bellan et al.
201646
Mixed, 92%
viral
Ishak #1
42 ng/mL 64% 95% N/A 0.788 Bellan et al.
201646
Ishak $4
M2BP 2.21 C.O.I. 88.2% 78.7% PPV 58.9%,
NPV 94.5%
0.812 Toshima et al.
201550
HCV Metavir $3
1.00 C.O.I. 67% 70% PPV 53%,
NPV 81%
0.680 Nakamura et al.
201752
HBV Ishak $3
2.00 C.O.I. 69% 74% PPV 57%,
NPV 83%
0.795 Nakamura et al.
201752
HCV Ishak $3
1.57 C.O.I. 85.9% 74.6% N/A 0.879 Abe et al. 201553 NAFLD Metavir $3
1.40 C.O.I. 83% 90% PPV 69%,
NPV 95%
0.933 Umemura et al.
201554
PBC Metavir $3
3.70 C.O.I. 64.3% 83.3% N/A 0.747 Nishikawa et al.
201655
Autoimmune
hepatitis
Metavir $3
OPN 2.9 ng/mL 96.4% 94.1% N/A 0.957 Huang et al.
201077
HCV Metavir $3
124 ng/mL 97.1% 100% N/A 0.997 Matsue et al.
201579
HCV Metavir $3
PlGF 20.2 pg/mL 79% 63% N/A 0.758 Krawczyk et al.
201784
Mixed Desmet
Scheuer $2
21.9 pg/mL N/A N/A N/A 0.771 Krawczyk et al.
201784
Mixed Desmet
Scheuer $3
GDF15 1582.8 pg/mL 94% 67% N/A 0.854 Krawczyk et al.
201784
Mixed Desmet
Scheuer $2
1563.7 pg/mL N/A N/A N/A 0.901 Krawczyk et al.
201784
Mixed Desmet
Scheuer $3
HGF 2598 pg/mL 97% 64% N/A 0.849 Krawczyk et al.
201784
Mixed Desmet
Scheuer $2
2085.7 pg/mL N/A N/A N/A 0.888 Krawczyk et al.
201784
Mixed Desmet
Scheuer $3
Abbreviations: AUC, area under the curve; C.O.I., cut-off index; M2BP, Mac-2 binding protein; GDF15, growth differentiation factor 15; HGF, hepatocyte growth factor; N/A,
not available; NPV, negative predictive value; OPN, osteopontin; PlGF, placental growth factor; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.
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between the different markers is difficult because different
scoring systems have been used and different etiologies of
liver disease have been considered. However, the majority
of papers have evaluated the ability of the different molecules
to identify severe fibrosis.
Moreover, it is reasonable that these novel biomarkers
might find their best use within more complex algorithms
rather than in the simple measurement of their plasma
concentration. For example, the combined use of PlGF, HGF
and GDF15 has been recently tested. The sensitivity and
specificity of at least one marker positive for fibrosis stage F2
or higher was 84% and 72%, respectively, resulting in a
positive predictive value of 89% and a negative predictive
value of 63%. Moreover, the use of this approach was
effective in identifying 50% of those patients with a significant
degree of fibrosis, who would have been missed by a strategy
based only on transient elastography.84 Similar future studies
will establish which combination of biomarkers will prove to
represent a breakthrough for the non-invasive assessment of
fibrosis.
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